Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tiludronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.39 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.39 |
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.38 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 0.70 |
| ▸ | MMP8 | P22894 | 2/20 | 0.70 |
| ▸ | MMP14 | P50281 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiludronic Acid SCHEMBL8610150 | 0.98 | MMP1 (0.96) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL7159094 | 0.86 | MMP2 (0.77) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL8607912 | 0.84 | MMP2 (0.74) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL18988 | 0.82 | MMP2 (1.00) | MMP1MMP2MMP8MMP14HSD17B10 | |
| SCHEMBL29406152 | 0.81 | MMP1 (0.69) | MMP1MMP2MMP8MMP14TSHR | |
| Tiludronic Acid SCHEMBL3628467 | 0.81 | MMP2 (0.96) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL8607914 | 0.79 | MMP2 (0.92) | MMP1MMP2MMP8MMP14HSD17B10 | |
| SCHEMBL17954020 | 0.76 | MMP2 (0.79) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL2067280 | 0.74 | MMP2 (0.80) | MMP1MMP2MMP8MMP14HSD17B10 | |
| Tiludronic Acid SCHEMBL2326547 | 0.71 | MMP2 (0.75) | MMP1MMP2MMP8MMP14HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5491 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-117855631-B | Vanadium-based water-based zinc ion battery and preparation method of multi-element electrolyte thereof | 浙江瀚为科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117855631-A | Vanadium-based water-based zinc ion battery and preparation method of multi-element electrolyte thereof | 浙江瀚为科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-20200261543-A1 | COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2020-08-20 | — | — | US | claimed |
| EP-3694537-A1 | COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS | University of Copenhagen (DK) | 2020-08-19 | — | — | EP | claimed |
| EP-3526242-A1 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R | University of Copenhagen (DK) | 2019-08-21 | — | — | EP | claimed |
| US-20190231743-A1 | LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES | SERMONIX PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | claimed |
| WO-2019072963-A1 | COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2019-04-18 | — | — | WO | claimed |
| WO-2019022662-A1 | THE PREVENTION OF SIDE-EFFECTS IN CANCER AND FIBROSIS THERAPY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-01-31 | — | — | WO | claimed |
| WO-2018069442-A1 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R | UNIVERSITY OF COPENHAGEN (DK) | 2018-04-19 | — | — | WO | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |